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2Abstract
Glioblastoma multiforme shows multiple chromosomal aberrations, the impact of which
on gene expression remains unclear. To investigate this relationship and to identify
putative initiating genomic events, we integrated a paired copy number and gene
expression survey in glioblastoma using whole human genome arrays. Loci of recurrent
copy number alterations were combined with gene expression profiles obtained on the
same tumor samples. We identified a set of 406 ‘cis-acting DNA targeted genes’
corresponding to genomic aberrations with direct copy-number-driving changes in gene
expression, defined as genes with either significantly concordant or correlated changes
in DNA copy number and expression. Functional annotation revealed that these genes
participate in key processes of cancer cell biology, providing insights into the genetic
mechanisms driving glioblastoma. The robustness of the gene selection was validated
on an external microarray data set including 81 glioblastomas and 23 non-neoplastic
brain samples. The integration of array CGH and gene expression data highlights a
robust ‘cis-acting DNA targeted genes’ signature that may be critical for glioblastoma
progression, with two tumor suppressor genes PCDH9 and STARD13 that could be
involved in tumor invasiveness and resistance to etoposide.
3INTRODUCTION
Glioblastoma, the most devastating of the primary brain tumors, is characterized by
deregulation of multiple pathways, such as EGFR/PTEN/Akt/mTOR, TP53/MDM2/p14ARF
and p16INK4a/RB. Several signaling molecules in such cascades are already the targets
of therapies for glioblastomas but improvements remain modest from a clinical
standpoint (Stupp et al., 2007). Identification of further tumor biomarkers is thus needed
to provide new molecular targeted therapies. Important insights into tumor suppressor
genes and oncogenes will probably be provided by identifying genomic aberrations
inducing direct changes in gene expression, i.e., genes with expression levels either
significantly concordant or correlated with changes in DNA copy number.
DNA copy number alterations (CNAs) are generally more numerous in malignant tumors
than in benign ones, and could be classified as both causal and random genetic events.
Some CNAs have a direct effect on gene expression and are likely to be more critical
than others in the biology of cancer. Such CNAs can result either in the loss of tumor
suppressor gene function or in the over-expression and activation of oncogenes. Both
mechanisms constitute putative early oncogenic steps. A better understanding of the
initiating molecular determinants of malignant tumors will require the identification of the
CNAs that are functionally significant.
This task is particularly challenging for glioblastomas because of their highly rearranged
genome (Bredel et al., 2005 a, Maher et al., 2006), and by the large number of genes
that have been implicated at the transcriptome level (Nutt et al., 2003, Tso et al., 2006).
4Recently, some genome-scale studies of glioblastoma described the relationship
between DNA dosage and gene expression (Nigro et al., 2005, Liu et al., 2006, Phillips
et al., 2006), but with some weaknesses: (1) intra-tumor variability was not taken into
account; (2) direct gene level correlations were not really possible due to the use of low
resolution arrays; and most importantly (3) genome and transcriptome data sets were
unpaired, prone to provide false positives, and so to miss targeted genes.
In this study, we performed paired genome-wide analyses of glioblastoma, focusing on
genes that showed concordant CNAs and expression patterns. High-resolution maps of
chromosomal alterations were obtained by performing array-based comparative genomic
hybridizations (arrays CGH) on 19 glioblastomas. Gene expression profiling was carried
out on the same tumor samples, and compared to those obtained on non-neoplastic
brain samples. We validated and investigated our result in an independent publicly
available microarray data set of 81 glioblastomas and 23 normal brains. The associated
annotation and network analyses provide insights into the genetic mechanisms driving
glioblastoma.
5MATERIALS AND METHODS
Tissue Samples
A total of 76 glioblastomas and 8 normal brain samples were used in this study. Fresh-
frozen glioblastoma samples from patients admitted to the Neurosurgery Departments of
Brittany University Hospitals (Rennes and Brest) were collected with informed consent
and subjected to WHO classification. Histology was confirmed by hematoxylin-eosin
staining of paraffin-embedded blocks. The non-neoplastic brain tissues were obtained
from normal white matter area taken from patients undergoing surgery for chronic
epilepsy. For microarray and array CGH hybridization, a set of 19 glioblastoma and 4
normal brain samples were used. Blood was available for all these patients. Each snap-
frozen tumor block was cryodissected in 10µm sections. The first section as well as
sections obtained every 100µm were stained to select tissue with at least 70 percent of
tumor cells and to exclude necrotic areas and widespread blood vessels. To allow a
paired and accurate comparison between closely related biological materials, the
adjacent sections were alternatively pooled in different tubes for RNA and DNA
extraction. For subsequent real-time reverse transcription-PCR validation of selected
genes, we used an independent set of 57 glioblastoma samples.
Nucleic Acid Preparation
Tumor DNA was extracted according to manufacturer’s instructions (NucleoSpin Tissue
Kit, Macherey Nagel, Düren, DE). Blood DNA (reference) was isolated from peripheral
blood leucocytes using a classical saline extraction. Total RNA was isolated using
Macherey-Nagel NucleoSpin RNAII Kit. RNA integrity was confirmed using the Agilent
62100 Bioanalyzer (Agilent, Palo Alto, CA).
Arrays CGH Profiling
Genomic analyses were performed on Human 44K Agilent arrays CGH (Agilent
Technologies, Santa Clara, CA) according to the manufacturer’s protocol. Briefly, 5µg of
DNA were double-digested (AluI and RsaI, Promega, Madison, WI, USA). Tumor DNA
and reference DNA were both labeled by random priming with Cy3-dCTP and Cy5-dCTP
for dye-swap experimental design. Tumor and reference DNA were pooled and
hybridized (65°C, 48h). Arrays were washed and scanned on an Agilent G2565BA
microarray scanner. Data were extracted and flagged with the Feature Extraction
software (FE v9.4.1, CGH_44k_1005 protocol). Data preprocessing was carried out
using limma (R package) from Bioconductor (Smyth et al., 2005). Values were median
normalized and fluorescence log2 ratios were calculated as the average of two-paired
arrays (dye-swap) except for one pair of arrays from which only one array met the quality
criteria. Missing values were imputed with the k-nearest neighbors method implemented
in impute (R package).
Array CGH Data Analysis
Log2 ratios (tumor vs. reference) of probe intensities were plotted according to their
genomic position, chromosome by chromosome. DNA copy number alterations were
identified using the Gain and Loss Analysis of DNA algorithm (Hupé et al., 2004)
implemented in GLAD (R package). This method uses Adaptive Weights Smoothing
(AWS) procedure to detect breakpoints from array CGH profiles, and assigns a copy
number status to each altered or normal chromosomal region. A ‘segmented’ data set
7was generated by determining uniform copy number segment boundaries and by
replacing normalized log2 ratio for each probe by the calculated smoothing values. As
done in the multiple myeloma study of Aguirre et al. (2004), distribution of the smoothing
values was used to define thresholds for the analysis of hemizygous deletions,
homozygous deletions, gains and amplifications. Thresholds for low-copy number gain
and hemizygous deletion were set at -0.15 and +0.15 respectively (±6 SD of the middle
75% of the data). Thresholds for high amplitude events were chosen at +0.9 for
amplification and at -0.40 for homozygous deletion. Minimal common regions (MCRs)
were defined as loci with CNAs in at least two samples; one of them showing an extreme
CNA event defined by thresholds +0.29 and -0.29, <99% and <1% quantiles.
Unsupervised hierarchical clustering was done on the ‘segmented’ data matrix using the
Support Tree option in MeV (http://www.tigr.org/software/tm4/midas.html). Consensus
clusters (average linkage and Pearson correlation metric) were built by bootstrap.
Gene Expression Profiling
Gene expression profiling was performed using the Agilent Whole Human oligo-
Microarray Kit 4x44K multiplex format (Agilent Technologies, Santa Clara, CA, USA),
with manufacturer’s recommended procedures for microarray-based one-color
(http://www.chem.agilent.com/temp/rad37FF4/00064034.pdf). Briefly, 350ng of total RNA
with control RNA Spike In were amplified and labeled with Cy3-CTP (Agilent
Technologies, Santa Clara, CA). 1.65µg of Cy3-labeled RNA were hybridized (65°C,
17h) per array. The processed Multiplicative Detrend FE data (FE v9.4.1, GE1-
v5_91_0806 protocol) of scanned images were median normalized and missing values
were imputed (limma and impute, R packages).
8Expression Data Analysis
Analysis of gene expression was conducted to highlight the genes differentially
expressed between glioblastomas and normal brain tissues. The significance in
differential gene expressions was determined using standard Student’s t-test of two
groups. To account for multiple hypothesis testing, we computed adjusted p-values by
controlling the false discovery rate (FDR) with the Benjamini & Hochberg (BH) procedure
implemented in multtest (R package). Differentially expressed genes were defined as
follows: BH adjusted p-value<0.01 and absolute mean log2 ratio (glioblastoma vs. mean
normal brain) greater than 2.
The complete dataset has been submitted to the Gene Expression Omnibus Data (GEO)
public database at NCBI, and the accession number is GSE10878.
Integrated Copy Number and Expression Analyses
Combination of genome and transcriptome datasets was done gene-by-gene for all the
annotated genes that were present on both arrays. We used two approaches to identify
all the genes whose transcription levels were potentially affected by DNA alterations. A
schematic of our approach is provided in Figure 1. In the Targeted study (Figure 1 A), we
identified the genes differentially expressed between glioblastoma and normal brain (BH
p-value<0.05), located in MCR and concordant to the corresponding CNA, e.g. we
selected those that were over-expressed or under-expressed and located in a region of
gain or loss respectively. In the Correlation study (Figure 1 B), we evaluated the direct
influence of copy number alterations on gene expression in MCR. We identified the
9genes with highly correlated DNA ‘segmented’ values and expression patterns
(Pearson’s correlation coefficient up to 0.7).
Gene Ontology, Canonical Pathway, and Functional Network Analyses
Functional annotation analyses were performed with the NIH-DAVID software (version
2.1b, http://david.abcc.ncifcrf.gov/) and the method developed by Aubry et al. (2006). We
used the first method with the parameters: GOTERM_BP_ALL, KEGG_PATHWAY and
SP_PIR_Keywords; the significance threshold was set on a p-value<0.05 with Benjamini
multiple testing correction. The second one was used to provide deeper informative
annotations by combining evidence and literature with Gene Ontology Annotation
database and PubGene biomedical literature index. Functional network analyses were
executed using the Web-delivered application from Ingenuity Pathways Analysis4 that
enables the visualization and exploration of molecular interaction networks in gene
expression data.
Real-time quantitative PCR (Q-PCR) for PCDH9 and STARD13
Q-PCR reactions were done with the 7900HT Fast Real-Time PCR System using the
SYBR™Green PCR Master Mix (Applied Biosystems®). B2M, β-2 micoglobulin, RNA
was chosen as internal control. Calibration was done with FirstChoice® Human Brain
Reference Total RNA (Applied Biosystems®). The relative amounts of the gene
transcripts were determined using the ΔΔCt method, as described by the manufacturer.
The following forward (F) and reverse (R) primers were designed using Primer3 (v.0.4.0):
B2M, F: 5’-TCCAACATCAACATCTTGGT-3’ and R: 5’-TCCCCCAAATTCTAAGCAGA-3’;
P C D H 9 ,  F: 5’-GCATATTGTCACTTAGGTCAAACCA-3’ and R: 5’-
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GTCATGCCTTAACAAAAACCTCCT-3 ’ ;  S T A R D 1 3 ,  F :  5 ’ -
TGCTAATGGATCGAATGTGCTT-3’ and R: 5’-TTCTCCAACACCAGTTGCTAAATC-3’.
Comparison with published expression data
We evaluated the robustness of gene selections on a publicly available microarray data
set. The expression data from Sun et al. (2006) (GDS1962) were used to generate the
comparison data set of gene expression changes between glioblastoma (n = 81
samples) and normal brain (n = 23 samples). The GDS1962 was downloaded from the
Gene Expression Omnibus database5 and managed with GEOquery (R package). A data
matrix was generated by R programming, with the mean centered and scaled values
corresponding to the processed data per array. We downloaded the annotation of the
Affymetrix U133 Plus 2.0 Array platform from the Ensembl website. We retrieved the
genes we were interested in by identifying probe sets with gene symbols. For heatmap
representation, values were expressed as log2 ratio of glioblastoma vs. mean of all
normal brain samples.
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RESULTS
Recurrent and Novel Genomic Changes in Glioblastoma
Glioblastomas (n=19) were analyzed by array CGH in a dye-swap experiment design to
support the normalization step and to provide a robust evaluation of the genomic
profiles. Only somatic changes were defined since each tumor DNA was hybridized with
the corresponding patient blood DNA. Segmentation analysis identified large aberrations
at the genome level as well as focal higher-amplitude recurrent CNAs (MCRs). A
summary of the CNAs is shown in Figure 2 A. The most frequent imbalances were: gain
of chromosomes 7 (73%, gain of both 7p and 7q in 47%, 7p alone 10%, and 7q alone in
16%) and 20 (16%); and loss of 9p (58%), chromosome 10 (58%), parts of chromosome
13 (31%), and 22q (21%).
The MCRs (2285 DNA segments and 4816 genes) corresponding to either
amplification (log2 ratio > 0.9) or homozygous deletion (log2 ratio < -0.40) are presented
in Supplementary Table 1 (A and B). These high-amplitude events span a median size of
8.4Mb with an average of 11 known genes. The following previously well-characterized
amplicons were identified: co-amplification of PDGFRA, KIT and KDR (three tumors), co-
amplification of EGFR, SEC61G (six cases), co-amplification of CDK4 and MDM2 (one
tumor) and amplicon at 1q32.1 (two cases) including a gene encoding a catalytic subunit
of Pi3k (PIK3C2B) (Knobbe et al., 2003). The well-known deletion of CDKN2A and
CDKN2B with co-deletion of the putative tumor suppressor gene MTAP (Schmid et al.,
2000) was found in four cases. The recently identified glioblastoma deletion of tumor-
suppressor gene CDKN2C was also present in one tumor (Solomon et al., 2008). In
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addition, we identified the following new amplicons: at 20q11-13, including POFUT1
known to be essential for Notch function (Kroes et al., 2007), at 9p22.1, including
DNAJA1 that encodes a co-chaperone of heat shock protein 70 (Wang et al., 2006) and
at 11p13, including PAX6 (Daugaard et al., 2007). New homozygous deletions included
particularly DKK1 (10q11.2) that is a Wnt/β-catenin pathway inhibitor shown to be pro-
apoptotic in brain tumor cells (Shou et al., 2002) and other genes (CNTNAP3, 9p13.1;
GLUD2, in Xq24, and, BAGE and BAGE4, in 21p11.1).
MCRs Cluster Glioblastoma Around EGFR and STARD13 Status
To probe the organization of MCRs across the tumor set, we performed unsupervised
hierarchical clustering of glioblastomas in the space of MCRs (without taking into
account the sex chromosomes). Cluster analysis (Figure 2 B) emphasized common
recurrent aberrations, including the gain of whole chromosome 7 and losses of
chromosome 10 and 9p. Notably, cluster analysis highlighted two sample groups
depending apparently on whether EGFR (7p11.2) was amplified or not (subtype-1 and
subtype-2, respectively). In addition, it showed that three glioblastomas (one with EGFR
amplification, the others without gain of chromosome 7) had particular genomic profiles
(see Supplementary Table 2). For these three patients, neither re-analysis of the
histological nor clinical data was able to phenotypically appreciate these particularities.
In order to more directly assess the relation between MCRs and the two groups
(subtype-1 and subtype-2), we applied a supervised analysis using a standard Student’s
t-test. Supervised analysis showed that the two subtypes exhibited distinct patterns of
MCRs (Supplementary Table 3). In particular, it confirmed that all the subtype-1-
glioblastomas but none of the subtype-2-glioblastomas carried EGFR amplification at
13
7p11.2 locus (p=0.006). It also showed that: (i) subtype-1 presented more frequent
hemizygous deletions at 13q31-13q34 (p=0.01) and 13q12-13q21 (p=0.03); (ii) gains at
7p21.3-p21.2, 7q21.11, 7q21.2 and 7q31.1-q34 were more frequent (p  < 0.01) in
subtype-2 (77-88%) compared to subtype-1 (28-42%). We also investigated these
differences at the transcriptome level (Student’s t-test with BH correction, comparing
expression values between subtype-1 and subtype-2 for genes located in the aberrant
regions on chromosome 7 and 13q). Only two differential gene expressions were
highlighted: EGFR  over-expression (p=0.011) and STARD13  under-expression
(p=0.036).
Glioblastoma Expression Profiling Identifies Huge Amount of Alterations
Evaluation of genes that are differentially expressed in glioblastoma versus normal brain
was undertaken using a standard Student t-test with BH correction (p<0.01) and
absolute average log2 ratio greater than 2. Expression profiling identified 664 over-
expressed genes in glioblastoma, including 56 genes over-expressed greater than 30-
fold, and 1224 under-expressed genes, including157 genes under-expressed greater
than 30-fold. A list of all the identified genes is provided in Supplementary File 1. From
the top ten of the over-expressed genes we identified the antiapoptotic gene
BIRC5/survivin (Blum et al., 2006) and the transcription factor E2F2 (Okamoto et al.,
2007), the activities of which have been already linked to glioblastoma. We also found
two highly expressed mitotic kinases, PBK  and BUB1 , and a potential cell cycle
regulator, DLG7/HURP, that have not been previously reported in glioblastoma.
Proliferation-related genes were also included among the highly expressed genes. Some
of them were previously well described as participating in glioblastoma progression, such
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as UBE2C (Bredel et al., 2005 b), MKI67 (Raghavan et al., 1990), TOP2A (van den
Boom et al., 2002), TNC (Sarkar et al., 2006), CHI3L1/YKL-40 (Tanwar et al., 2002),
MELK (Liu et al., 2006) and CD44 (Ylagan et al., 1997). The others, NCAPG, KIF20A,
CENPA and RRM2, are novel glioblastoma-associated genes with reported functional
roles in cytokinesis and/or cell proliferation (Geiman et al., 2004, Wonsey et al., 2005).
Regarding the under-expressed genes, we identified some with known tumor suppressor
functions in glioma (CHD5 and LGI1). CHD5  was identified last year as a tumor-
suppressor that controls proliferation, apoptosis, and senescence via the p19(Arf)/p53
pathway in glioma (Bagchi et al., 2007). It has been suggested that the leucine-rich,
glioma-inactivated gene 1 (LGI1) gene is a candidate tumor suppressor gene involved in
progression of glial tumors (Chernova et al., 1998). In addition, four components of the
Wnt/β-catenin signaling pathway were highly under-expressed: two Wnt antagonists,
WIF1 and SFRP1, and PPP2R2C (PP2A) and WNT10B (Kirikoshi et al., 2002). Such
disruptions may result in an improper function of the Wnt/β-signaling pathway leading to
aberrant cell proliferation and therefore explaining part of the glioblastoma progression.
Functional annotation of the highly differentially expressed genes (greater or less than
30-fold) underlined distinct biological processes according to groups of over- or under-
expression. Highly over-expressed genes were significantly associated with the
regulation of the mitotic cell cycle, and more precisely with the following
GOTERM_BP_ALL: M phase (p=5.7e-7), microtubule-based process (p=3.9e-3) and
sister chromatid segregation (p=0.01). Highly under-expressed genes were significantly
associated with cell communication (p=1.8e-3), cell-cell signaling (p=3.1e-9) and
neurophysiological process (p=4.9e-5).
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Identification of the glioblastoma DNA targeted genes
To identify targeted genes, we used the paired array CGH and transcriptome data sets,
measured on the same glioblastomas and restricted to MCRs. We combined these two
paired data sets to focus only on the genes for which the expression was affected by
aberrant copy number variations. Two possibilities were evaluated: genes with
expression levels significantly concordant with changes in DNA copy number (Targeted
study) and genes with expression levels directly correlated with such changes but not
necessarily with a significant differential expression in all glioblastomas (Correlated
study) (see Materials and Methods, Figure 1, for schematic representation).
The Targeted study showed that DNA copy number influenced gene expression
across a 13.8% range of MCRs, corresponding to 261 Significant Targeted Genes
(STGs) that were differentially expressed and concordant with MCR patterns.
Representation of DNA aberrations and corresponding gene expression on two mirrored
heatmaps clearly shows the unbalanced distribution of concordant over- and under-
expressed genes on chromosomes (Figure 3 A). The 95 STGs found to be highly
expressed in gain of regions were located in chromosome 1 (1p32.1), 4 (4q11-4q12), 7,
12 (12p11) and X (Xq24) and the 166 STGs under-expressed in deleted regions were
located in 9p, chromosome 10 and 13q. Functional annotation analyses of the STGs
were performed by taking into account under- and over-expressed groups separately.
Significant enrichments were found with DAVID: the over-expressed STGs were
particularly related to developmental processes (GOTERM_BP_ALL: development,
morphogenesis and SP_PIR_KEYWORDS: developmental protein) and the under-
expressed STGs to mRNA splicing (SP_PIR_KEYWORDS: alternative splicing). The
method developed by Aubry et al. (2006) provided more details on tumorigenesis-related
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processes linked to STGs including cell cycle (mitosis and apoptosis), cell adhesion,
DNA repair and angiogenesis (Figure 3 B). To understand how STGs are related, they
were replaced in pathways and molecular interactions established on the Ingenuity
knowledge base. Networks and associated functions and disease were scored and
checked for significance. The most relevant one was built around EGFR and displayed
high-level functions in cancer and neurological disease. It contained 27 STGs (Figure 3
C), including the GBM-related genes CAV1, DMBT1, EGFR, KDR and MGMT. The over-
expressed STGs were notably linked to cell proliferation and movement.
The Correlated study focused on the DNA alterations affecting gene expression on
a distinct, individual and isolated manner. To achieve this, we performed direct
correlation analyses of copy number and expression data on a gene-by-gene basis
throughout the genome. Transcription levels were highly correlated to genomic patterns
for 159 Correlated Genes (CGs), representing only 4.1% of the genes located in MCRs.
The CGs were located on chromosomes 1, 4, 7, 9, 10 and 13, as for the STGs, but also
on chromosomes 17, 20 and 22. The strong influence of DNA copy number on the CGs
expression is evident by examination of the heatmap representations of CGs data for
DNA aberrations and gene expression (Figure 4 A). The overall patterns of gene
amplification and increased gene expression are concordant, i.e., a significant fraction of
the highly amplified genes appear to be correspondingly highly expressed. Such
concordance is also found for part of the genes located in losses. Functional annotation
of CGs highlighted Gene Ontology terms (biological processes) mostly associated with
cell cycle, DNA repair, RNA processing, and brain development (Figure 4 B). The top-
scoring networks (Figure 4 C), built around EGFR and PDGF, contained glioma-related
genes (CDKN2A, CDKN2B, EGFR and MLL3), genes that play a role in hematological
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disorder (CDKN2A, CDKN2B, EGFR, GIT1, MPDZ, NT5C3, OPRS1, PDGFA, PLCG1,
RALA, SLC25A13, SRPK2 and TIMM23) and genes involved in cell division process
(CDKN2A, CDKN2B, DMTF1, PLCG1 and ZC3HC1).
A Targeted Genes Signature for Glioblastoma
Following the results of both Targeted and Correlated analyses, we determined a set of
406 genes constituting the glioblastoma targeted genes signature. Fourteen genes were
identified in both analyses. To evaluate the relevance of this glioblastoma genomic
signature, we used a publicly available microarray data set (GDS1962) of 81
glioblastomas and 23 normal brain samples, from the study by Sun et al. (2006). We
were able to map 369 of our 406 selected genes on the Affymetrix U133 Plus 2.0 Array
platform, and generated the corresponding data matrix. We performed a Student t-test
on this data table to identify the genes that were differentially expressed between
glioblastoma and normal brain. With a risk level (BH) of 5%, we confirmed that 86% of
the 369 genes were differentially expressed in glioblastoma (92% for the Targeted study
and 73% for the Correlated study). More details are available in Supplementary File 2. A
heatmap representation of all the glioblastomas (81 from the Sun et al. study [external]
and 19 from the present study [local]) is provided in Figure 5 A. The strong similarity of
the red:green profiles between the two data sets (external and local) illustrate the strong
robustness of the targeted genes signature. Network analysis provided two top scoring
networks: the first one (Figure 5 B) was built around Rb and NfκB and the second
(Figure 5 C) around Akt, EGFR and PDGFR. Overlaid functions (‘proliferation of cells’,
‘hematological disorder’ and ‘developmental process of tumor cell lines’) were mostly
associated to over-expressed genes. Both networks included a substantial number of
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genes that have been implicated in glioblastomagenesis.
To go further in the validation of the glioblastoma targeted genes signature, we probed
separately the organization of the Targeted genes across the tumor set from the
Correlated genes (Figure 6). We performed unsupervised hierarchical clustering of all
the tumors in the space of each set of genes. The Targeted cluster analysis (Figure 6 A)
defined two groups of tumors. However, the genes signature did not provide a clear
distinction between the two groups, illustrating the homogeneous expression of the
Targeted genes in glioblastoma. The Correlated cluster analysis (Figure 6 B)
emphasized the heterogeneous part of the signature, also grouping glioblastomas into
two subtypes, mainly depending on whether genes mapping to 7p11.2 were highly over-
expressed or not and whether CDKN2A and CDKN2B were deleted or not.
PCDH9 and STARD13 were considered interesting due to their biological function and
because their under-expression was strongly correlated to the corresponding genomic
state. PCDH9 and STARD13 under-expression was validated by RT Q-PCR on an
independent set of 57 glioblastoma samples and on the same panel of glioblastomas
(Figure 7). It was also confirmed by the GDS1962 analysis.
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DISCUSSION
Glioblastomas show numerous DNA alterations of varying size and location, as well as
large transcriptome modifications. The functional annotation analyses suggest that the
molecular alterations occurring in glioblastoma promote cell growth, proliferation, survival
and apoptotic resistance. However, identifying high-priority biomarkers by this way is still
challenging. Consequently, we sought to identify targeted genes by integrating data on
the genome and transcriptome levels. To achieve this task, we implemented a dual
strategy that delineates genes with either significantly concordant or correlated changes
in expression and in copy number.
A major advantage of choosing a dual strategy is that it bypasses limitations due to a
small number of cases and due to inter-tumor heterogeneity. Indeed, a great part of the
genes with copy number driving changes in expression are likely to be functionally
significant even if occurring in only few cases. In our study, such genes were surveyed
by the Correlation study. This is well illustrated in our analysis of CDKN2A and CDKN2B.
These two genes are altered at the DNA level with an impact on transcription. The
Correlation study but not the Targeted one identified these two genes, which were also
validated by external data analysis. Moreover, the Correlation study and the validation
step help to balance the lack of statistical power due to our small sample size cohort.
The dual strategy delineated two sets of genes that appear to have distinct biological
relevance. The genes identified by the Targeted study had homogeneous transcriptome
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modifications in glioblastomas. Even though gene expression was affected in almost all
tumors, it was not related to CNAs in all glioblastomas.  The homogeneous
transcriptome signature must involve other regulatory mechanisms such as regulations
by transcription factor, miRNA and DNA methylation. These widespread homogeneous
changes are related to mitotic defects, chromosome segregation errors, disruption of cell
adhesion processes, activation of DNA repair, escape from apoptosis and angiogenesis.
Moreover, our network analysis revealed a top-scoring pathway potentially affecting
glioblastoma cell invasion. It is therefore tempting to assume that the Targeted genes
correspond to changes highly essential for glioblastoma development and that they are
the most likely candidate oncogenes and tumor-suppressor genes linked to
tumorigenesis.
In contrast, the genes identified by the Correlation study have an expression directly and
highly linked to the DNA copy number status, consequently representing more sporadic
events. The two clusters of glioblastoma suggest distinct pathways leading to
glioblastoma development, raising the question whether these different sets of genes
combinations result from compensatory functions within genetic pathways or whether
they represent different clinical subclasses of glioblastoma. Our functional annotation
and network analyses provided some information, suggesting that part of the
heterogeneity was due to genes associated general cancer biology, as well as to genes
that control normal brain.
We also identified PCDH9 and STARD13 as potential tumor suppressor genes in
glioblastoma. PCDH9 is a protocadherin predominantly expressed in the nervous system
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and is highly similar to cadherin-related tumor suppressor precursor6. Three other
protocadherins, PCDH8, PCDH20, PCDH21, were shown to be under-expressed in the
Targeted study; PCHD20 is a candidate tumor suppressor in non-small-cell lung cancers
(Imoto et al., 2006). As these genes are likely to be involved in cell-cell interactions in the
glial cell compartment, it will be of interest to investigate the links between their low
expression levels, adhesion of glial cells and the promoted invasive growth of
glioblastoma. StAR-related lipid transfer (START) domain containing 13 (STARD13)
belongs, with DLC1, to the family of RhoGap proteins with START domains (Soccio et
al., 2003). The corresponding genes are frequently lost in hepatocellular and breast
carcinomas (Ching et al., 2003, Nagaraja et al., 2004). Both STARD13 and DLC1 are
suggested to be candidate tumor suppressor genes (Yuan et al., 1998, Ng et al., 2006).
Moreover, Hatch et al. have recently suggested that impairments of STARD13 gene can
participate in etoposide resistance via its role in ceramide signaling to the RhoA pathway
(Hatch et al., 2007). A temozolomide/etoposide chemotherapy regime is currently being
evaluated in trials for glioblastoma (Korones et al., 2003), and it will be of great interest
to study response to this treatment with regard to presence or absence of STARD13
deletions.
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FIGURES LEGENDS
Figure 1 — Outline of strategy to combine copy number alterations and gene
expression data. The ‘segmented’ data set (a) and its paired gene expression data set
(b), corresponding to the selected Minimal Common Regions (MCR), were used either
for Targeted study (A) or Correlation study (B). For the Targeted study, statistical
analysis (t-test) was performed and genes with BH P-values<0.05 and a concordant ratio
of expression were selected. For the Correlation study, the Pearson correlation
coefficient was calculated and the correlation matrix was generated. Each gene for
which the diagonal value was up to 0.7 was selected. Graphical displays illustrate the
possible case selections: (I) example of a gene under-expressed in a deleted region
(selected in the Targeted study); (II) example of a gene gained in 3 glioblastomas with
correlated over-expression in the corresponding tumors (selected in the Correlation
study); (III) example of a gene significantly over-expressed with expressions levels
correlated to the corresponding DNA dosage (selected in both studies).
Figure 2 — DNA Copy number alterations in Glioblastoma. A. Frequencies (%) of
significant copy number alterations across the samples in segmented data (y axis) are
plotted for each array CGH probe aligned along the x-axis in chromosomal order.
Red=gains, green=losses, dark red and dark green indicate amplification and
homozygous deletion, respectively. B. The result of the unsupervised hierarchical
clustering of glioblastoma samples based on the altered minimal common regions
(except chromosomes X and Y) is displayed. This clustering was done on ‘segmented’
data, using the Support Tree option in the TM4 microarray software suite (MeV), and
29
consensus clusters were built using bootstrapping with average linkage and Pearson
correlation as distance metric. Probes are ordered according to their genomic position
and chromosomes are noted below the heatmap. Colored tree branches denote the level
of support resulting from the resampling (black: 100% support, yellow: 60-70% support).
Transparent blue (subtype-1) and red (subtype-2) triangles were created to collect 2
principal groups of glioblastomas falling below terminal nodes in the tree using a fixed
distance threshold.
Figure 3 — Targeted study: 261 genes with significant differential expression
concordant to DNA copy number changes. The Targeted study identified 261 genes
in minimal common regions with concordant and significant differential expression. A.
CGH and expression profiles are plotted (right and left heatmap, respectively) on the y-
axis by genomic map positions, samples are on the same order on the x-axis. Indications
of minimal common regions are marked on the left. B. Results obtained by the combined
functional annotation method developed by Aubry et al. (2006). The sources of
annotation (goa: Gene Ontology Annotation database, pub: PubGene biomedical
literature index and goapub: both) are provided and for each of them, the number of
associated genes and p-values are reported. Groups of differentially expressed genes
(up and down) are also indicated. C. Map of the top-scoring network from the functional
network analysis is presented; nodes represent genes, with their shape representing the
functional classes of the gene products, and edges indicate the biologic relationship
between the nodes, which include physical and functional interactions. Associated
functions are also mapped.
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Figure 4 — Correlation study: 159 genes with expression highly correlated to DNA
copy number changes. The Correlation study identified 159 genes in Minimal Common
Regions with expression highly correlated with DNA copy number status (Pearson’s
correlation coefficient up to 0.7). A. CGH and expression profiles are plotted (right and
left heatmap, respectively) on the y-axis by genomic map positions, samples are on the
same order on the x-axis. Indications of minimal common regions are marked on the left.
B. Results obtained by the combined functional annotation method developed by Aubry
et al. (2006). The sources of annotation (goa: Gene Ontology Annotation database, pub:
PubGene biomedical literature index and goapub: both) are provided and for each, the
number of associated genes and p-value are reported. C. Map of the top-scoring
network from the functional network analysis is presented; nodes represent genes, with
their shape representing the functional classes of the gene products, and edges indicate
the biologic relationship between the nodes, which include physical and functional
interactions. Associated functions are also mapped.
 Figure 5 — The ‘cis-inducing DNA targeted genes’ define a robust genomic
signature grouping potential key initiating events in Glioblastoma. The ‘cis-inducing
DNA targeted genes’ signature, comprising the combined results from the Targeted and
the Correlated studies and validated by data from the Sun et al. Study, is given. A.
Expression profiles are plotted on the y-axis by genomic map positions and samples are
ordered on the x-axis by their study of origin (blue box for GDS1962 data and pink box
for our local data). Data values are expressed as log2 ratio between each glioblastoma
and the mean of all the normal brain samples. B. and C. Maps of the first two top-scoring
networks from the functional network analysis are presented; nodes represent genes,
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with their shape representing the functional classes of the gene products, and edges
indicate the biologic relationship between the nodes, which include physical and
functional interactions. Associated functions are also mapped.
Figure 6 — Gene expression pattern subgrouping and evaluation of the
homogeneous and heterogeneous part of the Glioblastoma ‘cis-inducing DNA
targeted genes’ signature. Results of the unsupervised hierarchical clustering analyses of
all glioblastomas (external data and Local data) based on the Targeted Genes (A) and on
the Correlated Genes (B) are displayed. These analyses were performed using the Support
Tree option in the TM4 microarray software suite (MeV), and consensus clusters were built
using bootstrapping with complete linkage and Euclidian as distance metric. Probes are
ordered according to their genomic position. Colored tree branches denote the level of
support resulting from the resampling (black: 100% support and red-pink: no support).
Transparent blue triangles were created to collect 2 principal groups of glioblastomas falling
below terminal nodes in the tree using a fixed distance threshold.
Figure 7 — Validation of PCDH9 and STARD13 genes by RT Q- PCR.
PCDH9 and DLC2 were deemed particularly interesting because of their significant
under-expression correlated to DNA alterations. Y-axis, mean relative level of mRNA
(log2 based on the reference and commercial brain RNA as calibrator in glioblastoma
(GBM) and non-neoplastic brain (N) samples); ** corresponds to p < 0.01.
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